Authorization

Merus Bispecific Antibody MCLA-128 Shows Encouraging Early Clinical Activity in Patients with Cancers Harboring NRG1 Gene Fusions

Tumor shrinkage observed in three patients harboring NRG1 fusions (two pancreatic, one non-small cell lung cancer) presented by investigators at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Of nine patients enrolled across the MCLA-128 Early Access Program and the eNRGy Clinical Trial, four of seven treated showed clinical activity, two are too early in treatment for first assessment Company to host investor call to review presented data and provide an update on MCLA-128 program on Monday, October 28th at 8:00 a.m. ETUTRECHT, The Netherlands, and BOSTON, Oct. 27, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage company developing innovative, full-length bispecific antibodies (BiclonicsA®), today announced initial clinical data for three patients with cancers harboring NRG1 fusions treated with MCLA-128 through an Early Access Program (EAP), and provided an overall update on the MCLA-128 clinical programs. Data on the three EAP patients were presented today by study investigators at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, MA.Investigators from Memorial Sloan Kettering Cancer Center (MSKCC) provided a summary and initial data concerning the treatment of three cancer patients harboring NRG1 fusions with MCLA-128 at 750 mg administered intravenously every other week. A These patientsa?? NRG1 gene fusions were identified using RNA-based sequencing. Assessments from this EAP program were conducted locally at MSKCC. All three patients exhibited tumor shrinkage, symptomatic improvement and durability up to their most recent assessment. All three patients currently remain on treatment.
See also:
Leave a comment
News
  • Latest
  • Read
  • Commented
Calendar Content
«    Ноябрь 2019    »
ПнВтСрЧтПтСбВс
 123
45678910
11121314151617
18192021222324
252627282930